Kate Broderick on the INOVIO DNA vaccine candidate for COVID-19

Written by Kate Broderick (INOVIO Pharmaceuticals, CA, USA)


As an expert in the field, Kate Broderick, Senior Vice President, R&D, INOVIO Pharmaceuticals (CA, USA) spoke to Editor Lucy Chard on the DNA vaccine – INO-4800 – currently undergoing clinical trials for use against COVID-19.   Can you please give a short background of your career to date? Certainly, I went to Glasgow University, for both my bachelors and my PhD, my BSc was in genetics and then I went on to do a PhD in molecular genetics there. When I graduated with my PhD, I decided to see what life was like in another country. So, I moved...

To view this content, please register now for access

It's completely free